|
Market Closed -
NSE India S.E.
12:05:10 15/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 1,835.00 INR | -0.27% |
|
-3.17% | +6.70% |
| 09-09 | Sun Pharma Sets Up Global Treasury Center in India's GIFT City | MT |
| 09-09 | Sun Pharma Assigned Baa1, BBB+ Ratings by Moody's, S&P | MT |
| Market Cap | 4,403B 45.9B 39.76B 37.59B 34.04B 63.88B 64.36B 449B 173B 2,232B 172B 169B 7,120B | P/E 2027 * |
33.9x | P/E 2028 * | 28.7x |
|---|---|---|---|---|---|
| Enterprise Value | 4,132B 43.08B 37.31B 35.28B 31.94B 59.95B 60.4B 421B 162B 2,095B 162B 158B 6,682B | EV / Sales 2027 * |
6.35x | EV / Sales 2028 * | 5.58x |
| Free-Float |
44.39% | Yield 2027 * |
0.93% | Yield 2028 * | 1.08% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| SUNPHARMA | Delayed | |
Bombay S.E.
| SUNPHARMA | Delayed |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.27% | ||
| 1 week | -3.17% | ||
| Current month | -7.55% | ||
| 1 month | -4.92% | ||
| 3 months | +1.51% | ||
| 6 months | +1.85% | ||
| Current year | +6.70% |
| 1 week | 1,828 |  | 1,898.6 |
| 1 month | 1,828 | | 1,984.8 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 31/08/2025 | |
| Director of Finance/CFO | 58 | 30/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 31/08/2025 | |
| Director/Board Member | 73 | 24/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.27% | -3.17% | +13.51% | +60.43% | 46.06B | |
| +1.42% | -2.60% | +34.32% | +109.71% | 38.29B | |
| -1.80% | -5.00% | +5.19% | +71.75% | 11.65B | |
| -1.10% | -3.15% | -14.20% | +9.50% | 11.51B | |
| -0.95% | -0.76% | +18.18% | +146.45% | 9.17B | |
| +0.80% | +0.64% | +24.85% | +37.61% | 7.22B | |
| -1.96% | -3.27% | +11.22% | +174.06% | 7.12B | |
| +0.68% | -2.69% | +36.28% | -18.66% | 7.11B | |
| -2.15% | -5.49% | -45.74% | +9.75% | 4.99B | |
| -0.65% | -0.09% | +36.11% | +95.78% | 4.61B | |
| Average | -0.63% | -1.82% | +11.97% | +69.64% | 14.77B | |
| Weighted average by Cap. | -0.13% | -2.53% | +16.62% | +75.41% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.79B 5.88B 5.56B 5.03B 9.45B 9.52B 66.34B 25.52B 330B 25.49B 24.93B 1,053B | 729B 7.6B 6.58B 6.22B 5.64B 10.58B 10.66B 74.28B 28.58B 370B 28.55B 27.91B 1,179B |
| Net income | 130B 1.35B 1.17B 1.11B 1B 1.88B 1.9B 13.21B 5.08B 65.75B 5.08B 4.96B 210B | 154B 1.6B 1.39B 1.31B 1.19B 2.23B 2.25B 15.66B 6.02B 77.91B 6.02B 5.88B 248B |
| Net Debt | -271B -2.82B -2.44B -2.31B -2.09B -3.93B -3.96B -27.58B -10.61B -137B -10.6B -10.36B -438B | -338B -3.53B -3.06B -2.89B -2.62B -4.91B -4.95B -34.48B -13.27B -172B -13.25B -12.96B -547B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/09/26 | ₹1,835.00 | -0.27% | 1,437,151 |
| 11/09/26 | ₹1,840.00 | -1.13% | 1,445,071 |
| 10/09/26 | ₹1,861.00 | -0.21% | 1,178,648 |
| 09/09/26 | ₹1,864.90 | -1.11% | 1,396,896 |
| 08/09/26 | ₹1,885.90 | -0.48% | 1,422,627 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
